ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the ...
Complement component 3, often called C3, is an essential protein of the immune system. This protein plays a vital role in the body’s innate immune system, providing: the first line of defense against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results